Enterprise Value
687.9M
Cash
144.7M
Avg Qtr Burn
-61.17M
Short % of Float
17.88%
Insider Ownership
1.61%
Institutional Own.
92.78%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CIMERLI (CHS-201) (Lucentis biosimilar) Details Eye disease , Wet age-related macular degeneration , Age-related macular degeneration | Approved Quarterly sales | |
YUSIMRY (CHS-1420) (Humira® Biosimilar (adalimumab)) (Anti-TNF) Details Arthritis, Psoriasis, Inflammatory disease | Approved Quarterly sales | |
UDENYCA® (pegfilgrastim-cbqv) Biosimilar Details Cancer, Chemotherapy-induced neutropenia | Approved Quarterly sales | |
Toripalimab (anti-PD-1 antibody) + Chemotherapy Details Nasopharyngeal carcinoma | BLA FDA meeting | |
Toripalimab (anti-PD-1 antibody)(JUPITER-06) + Chemotherapy Details Esophageal Squamous Cell Carcinoma | Phase 3 Update | |
Toripalimab +/- CHS-006 (anti-TIGIT) (anti-PD-1) Details Solid tumor/s, Non-small cell lung carcinoma, Hepatocellular carcinoma | Phase 1/2 Data readout | |
CHS-131 Details Multiple sclerosis, Non-alcoholic steatohepatitis | Failed Discontinued | |
Toripalimab (CHS-305) Biosimilar (bevacizumab) + Chemotherapy Details Cancer, Small cell lung cancer | Failed Discontinued | |
Toripalimab (CHS-305) Biosimilar (bevacizumab) + anti-TIGIT Details Non-small cell lung carcinoma, Cancer | Failed Discontinued |